|
|
- IRMS - Nicolae Testemitanu SUMPh
- 1. COLECȚIA INSTITUȚIONALĂ
- MedEspera: International Medical Congress for Students and Young Doctors
- MedEspera 2026
Please use this identifier to cite or link to this item:
http://hdl.handle.net/20.500.12710/33913
| Title: | EXPERIMENTAL BIOSIMILAR PRODUCTION LINE IMPLEMENTATION AT NICOLAE TESTEMIŢANU STATE UNIVERSITY OF MEDICINE AND PHARMACY |
| Authors: | Cazacu, Radu Vladimir, Valica |
| Keywords: | biosimilar medicines;experimental manufacturing;biopharmaceutical process development |
| Issue Date: | 2026 |
| Publisher: | Centrul Editorial-Poligrafic Medicina |
| Citation: | Cazacu, Radu; Vladimir, Valica. EXPERIMENTAL BIOSIMILAR PRODUCTION LINE IMPLEMENTATION AT NICOLAE TESTEMIŢANU STATE UNIVERSITY OF MEDICINE AND PHARMACY. In: MedEspera 2026, p. 93. ISBN 978-9975-82-486-6. |
| Abstract: | Introduction. Biosimilar medicines are increasingly important in pharmacotherapy because they can expand access to complex biologic treatment and may reduce costs. In many universities, however, biosimilar development is taught mainly theoretically. At Nicolae Testemitanu State University of Medicine and Pharmacy of the Republic of Moldova, no integrated platform previously existed to demonstrate the full experimental workflow of such products. Aim of study. To implement an experimental biosimilar production line within the university and develop the protocols, SOPs, and training framework needed to simulate end-to-end manufacture of a recombinant model product at small experimental scale, with educational and research relevance. Methods and materials. A pilot academic platform was organized as a sequential workflow including medium preparation, inoculation/microbiology, fermentation, and purification. Recombinant somatropin was selected as the model product, and Pichia pastoris as the expression system. The workflow covered medium preparation, cultivation, cell bank creation, fermentation, separation, purification, and analytical training elements. The process was adapted from a reference protocol to small-volume production suitable for student participation under controlled conditions, including class D clean area organization, personnel SAS, and HVAC/HEPA-supported infrastructure. Results. The line was organized and made functional as a complete educational and research platform. Conditions were created for practical training of students and doctoral candidates, who already participate in sequential stages of the process, from medium preparation and conditioning to inoculation, fermentation, and separation. The platform enables small groups of 3-4 trainees to engage directly with each technological stage and supports semester-based product-oriented training. This approach improves understanding of process continuity, traceability, and the relationship between upstream and downstream operations in biopharmaceutical production. Work is also ongoing to adapt a new growth medium because components of the parent protocol have become difficult to source. Conclusions. This platform demonstrates the feasibility of integrating biosimilar-oriented bioprocess training into pharmaceutical higher education through a complete upstream-downstream experimental workflow. It also creates a foundation for translational research, protocol refinement, and future expansion of academic biopharmaceutical training. |
| metadata.dc.relation.ispartof: | MedEspera 2026. The 11th International Medical Congress for Students and Young Doctors, 6-8 May 2026 |
| URI: | https://medespera.md/documents/abstract-book-4.pdf https://repository.usmf.md/handle/20.500.12710/33913 |
| ISBN: | 978-9975-82-486-6 |
| Appears in Collections: | MedEspera 2026
|
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.
|